Tyr4
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.0.1
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr4  -  GSTP1 (human)

Site Information
____MPPyTVVyFPV   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 462289
Available spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 8 ) , mass spectrometry ( 2 , 3 , 4 , 5 , 6 , 7 , 9 ) , mutation of modification site ( 8 ) , western blotting ( 8 )
Disease tissue studied:
brain cancer ( 8 ) , glioblastoma ( 8 ) , glioma ( 8 ) , breast cancer ( 9 ) , breast ductal carcinoma ( 9 ) , gastric cancer ( 6 ) , gastric carcinoma ( 6 ) , leukemia ( 1 ) , acute myelogenous leukemia ( 1 ) , lung cancer ( 4 , 5 ) , non-small cell lung cancer ( 2 , 4 , 5 ) , non-small cell lung adenocarcinoma ( 2 , 4 , 5 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
EGFR (human) ( 8 )
Kinases, in vitro:
EGFR (human) ( 8 )
Treatments:
EGF ( 8 )

Downstream Regulation
Effects of modification on GSTP1:
enzymatic activity, induced ( 8 ) , protein conformation ( 8 )

References 

1

Zhou Y, et al. (2018) Glutathione-Transferase Pi Prevents Sepsis-Related High Mobility Group Box-1 Protein Translocation and Release. Front Immunol 9, 268
29520271   Curated Info

2

Rikova K (2013) CST Curation Set: 18449; Year: 2012; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) MultiMab(TM) Rabbit mAb mix Cat#: 8954
Curated Info

3

Rikova K (2012) CST Curation Set: 14271; Year: 2012; Biosample/Treatment: cell line, Tumor pilot study 2mg/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

4

Possemato A (2011) CST Curation Set: 11919; Year: 2011; Biosample/Treatment: cell line, NCI-H3122/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

5

Possemato A (2011) CST Curation Set: 11920; Year: 2011; Biosample/Treatment: cell line, NCI-H3122/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

6

Possemato A (2011) CST Curation Set: 11926; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

7

Gu TL, et al. (2011) Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One 6, e15640
21253578   Curated Info

8

Okamura T, et al. (2009) Tyrosine phosphorylation of the human glutathione S-transferase P1 by epidermal growth factor receptor. J Biol Chem 284, 16979-89
19254954   Curated Info

9

Rikova K (2006) CST Curation Set: 1076; Year: 2006; Biosample/Treatment: cell line, HCC1395/serum starved; Disease: breast ductal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info